

MEDICINE

NEWS FROM THE DEPARTMENT OF MEDICINE

MATTERS

MESSAGE FROM THE CHAIR

APRIL 2023



Welcome to spring! The beautiful weather is certainly invigorating, and I hope everyone is taking time to get outside and enjoy the local region. This month we highlight the Division of Hematology and Oncology. This Division has grown more in the last decade than any other in the Department of Medicine, which has supported the development of Comprehensive Cancer

Center status. This is an amazing achievement but is really eclipsed by the amazing depth and breadth of the clinical care now provided at the University of Virginia. Patients now have access to cutting-edge therapies and experts in all areas of hematology and oncology. All of this in a small city! UVA now rivals the country's best cancer centers; this has indeed been a team effort. Initially led by Dr. Michael Williams and then supported by Drs. Tom Loughran, Karen Ballen, Rob Driecer, Liz Gaughan, and many others, this program is a true testament to what can be done at UVA. As you read through this edition of Medicine Matters, you will get a good sense of the faculty and staff's excellence, scholarship, and passion. They have brought hope and improved outcomes to so many; much more is to come!

With best wishes,

Mitchell H. Rosner, MD, MACP
Henry B. Mulholland Professor of Medicine
Chair, Department of Medicine



DEPARTMENT OF MEDICINE

MISSION


We are dedicated to preventing disease and treating illness, educating and inspiring future leaders in the field of internal medicine, and supporting innovative biomedical research.

VALUES

We strive for a sense of community, connection, and synergy among all faculty, staff, and trainees.

PLEDGE

We will conform to the highest ethical standards, uphold the values of our partner organizations, and give back to our community through public service.



[DoM WEBSITE](#) ▶

[GRAND ROUNDS](#) ▶

[HIGHLIGHTED DIVISION](#) . . . ▶

[MINDFULNESS MATTERS](#) . . . ▶

[GIVE TO DOM](#) ▶

[SUBSCRIBE](#) ▶



UVAHealth

DOM UPDATES & NOTES

DOM Financial Update

Department of Medicine Summary of Consolidated Financials FY21 as of February, 2023

	Budget YTD	Actual YTD	\$ Variance YTD
Work RVUs	808,745	779,548	(29,197)
Clinical Receipts (NPSR)	53,191,994	49,958,161	(3,233,833)
Total Revenues	142,493,322	144,709,084	2,215,762
Total Expenditures	141,197,375	141,096,330	101,045
Net Income	1,295,947	3,612,754	2,316,807

Summary Explanation of Variance:

For the fiscal year through February 2023 DOM reported a consolidated net gain of \$3.6M and a favorable variance to YTD net income budget of \$2.3M. Clinical receipts underperformed budget by \$3.2M due to unfilled positions, delayed starts, reduced bed capacity open and unsigned encounters and unplanned leave. Total revenues include \$1.0M deficit support revenue accrual, \$935K unbudgeted MOU support and \$2.0M unbudgeted gifts and \$1.6M Endowment revenue recorded for March through June.

Total expenditures variance is impacted by savings in personnel charges due to unfilled faculty countered by spending on unbudgeted new grant awards and faster spending on existing research studies.

DEPARTMENT OF MEDICINE MEDICINE GRAND ROUNDS UNIVERSITY OF VIRGINIA



Jie Sun PhD



Patricia Rodriguez-Lozano MD



Uta Erdbrügger MD



Angie Nishio-Lucar MD



Sandra Arcoraci

Awards and Achievements

Congratulations to **Dr. Jie Sun** (Division of Infectious Diseases and International Health) for being named the newly elected *Harrison Distinguished Teaching Professor of Medicine*. Check out his latest paper, *"Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19."*

Congratulations to **Dr. Patricia Rodriguez-Lozano** (Division of Cardiovascular Medicine), who now directs a new Women's Heart Program, multidisciplinary care tailored for women through three dedicated UVA Health clinics. [Read more...](#)

Congratulations to **Dr. Uta Erdbrügger** (Division of Nephrology), who will co-chair the 2023 annual meeting of the International Society for Extracellular Vesicles. [Read More...](#)

Congratulations to **Dr. Angie Nishio-Lucar** (Division of Nephrology), who has been selected as a Fellow of the American Society of Transplantation. [Read More...](#)

Congratulations to **Sandra Arcoraci**, who will be moving on from her position in the Division of Asthma, Allergy, and Immunology after completing her graduate studies. Thank you for your many contributions and dedicated service and best wishes for your future endeavors.

DOM UPDATES & NOTES

School of Medicine 2022 Faculty Awards and Endowed Professorships



The School of Medicine Dean's Office held its faculty awards ceremony on February 28, 2023, in the Claude Moore Education Building. This annual event recognizes faculty for their lasting impact on the success of our students and trainees, patients, colleagues, and the advancement of science and medicine. Congratulations to our Department of Medicine honorees! [Read More...](#)

Susan Kirk, MD, Associate Dean for Graduate Medical Education and Associate Professor of Medicine

Barbara Mann, PhD, Associate Professor of Medicine

Michael Ragosta, MD, Professor of Medicine - *Master Clinician Award*

Ira Helenius, MD, Associate Professor of Medicine – *Dean's Award for Clinical Excellence*

Ira Helenius, MD, Associate Professor of Medicine – *Dean's Award for Clinical Excellence*

Jennifer Kirby, MD, PhD, Associate Professor of Medicine – *Dean's Award for Clinical Excellence*

Rahul Sharma, PhD, Associate Professor of Medicine (Junior Faculty Award) – *Dean's Award for Excellence in Research*

Curtis Argo, MD, Associate Professor of Medicine – *Master Educator Award for Graduate Medical Education*

Firas El Chaer, MD, Assistant Professor of Medicine – *Graduate Medical Education Excellence in Mentorship Award*

2022-2023 Endowed Professorship Electees

Antonio Abbate, MD, PhD, *Ruth C. Heede Professor of Cardiology, Department of Medicine*

Laurie Archbald-Pannone, MD, *Claude Moore Associate Professor of Geriatrics, Department of Medicine*

Sue Brown, MD, *Gerald D. Aurbach Professor of Endocrinology, Department of Medicine*

Jonathan Lindner, MD, *Frances Myers Ball Professor in the Cardiovascular Division, Department of Medicine*

Jie Sun, PhD, *Harrison Distinguished Teaching Professor of Medicine, Department of Medicine*

DOM UPDATES & NOTES

Awards and Achievements



Neeral Shah, MD, Director of the Academy for Excellence in Education (left), and Meg G. Keeley, MD, Senior Associate Dean for Education. (Photo by Kay Taylor)

2023 Excellence in Education Week Highlights Educational Research and Innovations

The School of Medicine held its 18th annual Excellence in Education Week, February 20-24, 2023. The week, dedicated to education in academic medicine, highlights educational research and innovations among UVA faculty, staff, fellows, residents, postdocs, graduate students, and medical students. It also provides professional development and networking opportunities and connects the UVA community with internationally known educational researchers. [Read More...](#)

Newsweek Ranks UVA Medical Center No. 1 Hospital in Virginia

Congratulations All! University of Virginia Medical Center is ranked as the No. 1 hospital in Virginia and in the top 50 hospitals nationally in Newsweek's "World's Best Hospitals 2023" guide.

University of Virginia Medical Center is ranked as the No. 1 hospital in Virginia and in the top 50 hospitals nationally in Newsweek's "World's Best Hospitals 2023" guide.

Newsweek's rating criteria include recommendations from more than 80,000 medical experts in 28 countries, results from patient-experience surveys, and measures of high-quality care and patient safety.



Newsweek



**FOLLOW DOM
ON TWITTER**



Mindfulness Matters
A Newsletter from the UVA
Mindfulness Center

CONGRATULATIONS CLASS OF 2023! AND HAPPY MATCH DAY

LEARN MORE & VIEW PHOTOS

DOM UPDATES & NOTES

WELCOME ALL!

2023 - 2024 Medicine PGY 1 (Interns)

CATEGORICAL



Asrar Alimohamed
U South Carolina




Olivia Becker
Univ
Mississippi



Ashley Bolte
UVA



Ivonne Cedillos
Univ of Buffalo



Daniel Cook
MUSC



Shivali Desai
U South Carolina



Justin Elkhechen
Rutgers



Benjamin Emery
UVA



Jason Erno
MUSC



Abigail Erwin
LSU



Mackenzie Franklin
UT Austin



Hannah Laird
Univ
Mississippi



Cynthia Li
UVA



Mary McGrath
Ohio State



Caleb McKinney
Loma Linda




Stephen O'Connor
Indiana U



Tiago Palmisano
Rowan University



Elizabeth Panther
Med Coll Wisc



Parmida Parsa
U South Carolina



Hector Picon
Med Coll Georgia



Avneesh Sharma
VCU



Rishika Singh
U Tennessee



Gordon Smilnak
Northwestern



Nandan Srinivasa
GWU



Alyssa Tuan
Penn State



Drew Vipperman
UVA



Jessie Williams
VCU



Alice Win
Med Coll Georgia



Sara Young
Boston Univ

ABIMRP



Brandon Podyma
UVA



Samuel Chao
Wake Forest

PRIMARY CARE




Emily Jezewski
Nebraska



Katherine Kruse
UNC

OPHTHALMOLOGY



Ryan Madsen
Jefferson Med Coll



Claire Meyerovitz
U Massachusetts



Sedona Rosenberg
GWU



William Sanfelippo
Wake Forest

PRELIMINARY




Breanna Nguyen
Pitt



Gabrielle
Schwartzman
GWU

NEUROLOGY




Garima Agarwal
Marshall U



Andrew Azdell
VCU



Joseph Furr
LSU



Christina Salgado
Indiana U



Rhea Sharma
VCU



Olivia VanOsch
Rutgers

CONGRATULATIONS! CONGRATULATIONS! CONGRATULATIONS!

In the Media


Graduate Medical Education Program Achieves Citation-Free ACGME Accreditation for 10th Year (Medicine In Motion News)



For the 10th consecutive year, UVA's Graduate Medical Education (GME) program has been re-accredited by the Accreditation Council for Graduate Medical Education (ACGME) without a single citation. Associate Dean for Graduate Medical Education and Associate Professor of Endocrinology Susan Kirk, MD speaks about the importance of the accreditation.

[READ MORE](#)

UVA Health Seeing Cases of Drug-Resistant Stomach Illness (NBC29)



The CDC and doctors at UVA Health are warning of an increase in drug-resistant strains of a stomach bug. Dr. Bill Petri says the bacteria become more resistant to antibiotics every year.

[READ MORE](#)

UVA Kidney Disease Screening Awareness Program Holds First Ever Event (CBS19)



University of Virginia Health held its first KDSAP (Kidney Disease Screening and Assessment Program) Kidney Screen on Saturday, March 25th, at Mt. Zion First African Baptist Church. The team screened 35 patients and was able to identify patients with hypertension, hematuria, and/or proteinuria. People came from as far away as Pittsburgh, Northern Virginia (parents of students). Many thanks to Marissa Yee (UVA 4th year) and Dr. Tushar Chopra for leading the effort as well as the rest of the enthusiastic undergraduates (not all listed here), faculty, staff members and of course Dr. Li Li Hsiao, overall Director of KDSAP, Harvard Medical School, and David Simmons for coordinating with Mt Zion FABC.

[LEARN MORE](#)

Can't Sleep? Dr. Daniel O'Hearn Can Help (UVAToday)



Dr. Daniel O'Hearn, the medical director of the University of Virginia's Sleep Disorders Center, speaks about how to get better Zs.

[READ MORE](#)

DOM UPDATES & NOTES

In the Media

Community Conversation: Dr. Jeff Wilson with UVA Health (CBS19)



Dr. Jeff Wilson (Division of Asthma, Allergy, and Immunology) speaks with NBC29 Community Conversation about Alpha-Gal Syndrome.

WATCH

UVA Health Department Running Group Has “a running fever” (NBC29)



One award-winning infectious disease doctor is working towards a new personal record with help from his department at the University of Virginia Medical Center. The record has nothing to do with fighting illnesses, however.

WATCH

3 years into the pandemic, should you still worry about COVID? (Today.com)



Experts share how they're approaching COVID-19 prevention right now, including Dr. Taison Bell (Infectious Diseases and International Health)

LEARN MORE

Do You Have News You'd Like To Share on Medicine

Contact Kim Kelley-Wagner kak2cj@virginia.edu
434.328.0680

Alexander Podboy, MD's Study Finds Troubling Disparities in Esophageal Cancer Outcomes (Medicine In Motion)

Alexander Podboy, MD's Study Finds Troubling Disparities in Esophageal Cancer Outcomes, with lower-income people less likely to receive lifesaving treatment. Lower-income people are significantly less likely to receive a potentially lifesaving treatment for the fastest-increasing type of esophageal cancer – and are more likely to die from the disease, new research from UVA Cancer Center reveals.



READ MORE

DOM UPDATES & NOTES

Awards and Recognition

Insurance Requirements for Prior Authorization May Prompt ‘Devastating’ Delays (CNN)



Kathleen (Kate) McManus, MD, an assistant professor in the Department of Medicine's Division of Infectious Diseases, was interviewed by CNN about how prior authorization may cause devastating unnecessary delays.

[READ MORE](#)

COVID-19 Discovery Could Protect High-Risk Patients (UVA Newsroom)



New research from UVA's Jie Sun, PhD, and colleagues suggests a way to protect patients with obesity or diabetes from the runaway inflammation and dangerous blood sugar spikes that COVID-19 can cause. Such patients are at high risk for severe COVID-19, and, with the effectiveness of existing

COVID treatments waning, new treatment options are needed urgently.

[READ MORE](#)

[VIEW ON CBS19](#)

2 UVA Discoveries Advance to Sweet 16 in STAT Madness (UVA Today)



Discoveries from the School of Medicine's Kenneth Walsh, PhD, and John Lukens, PhD, are duking it out in the Sweet 16 of STAT Madness, an online tournament to determine 2022's biggest biomedical advance.

[READ MORE](#)

Faculty Spotlight: To Learn Grace Under Pressure, Study Dr. Taison Bell, Master of Flow (UVA Today)



Dr. Taison Bell's thoughtful approach to life helps him balance some of the "intense" aspects of being an "intensivist." For Bell, this is 40. Like that famous painting of "The Great Wave," his career has been a boat pointing toward an oncoming tsunami, and that's intentional. The bigger the wave, the more movement and change created. (Photo by Sanjay Suchak)

[READ MORE](#)

DOM UPDATES & NOTES

For Your Listening Pleasure

Episodes of the Podcast, “This Medicine Life” with Dr. Taison Bell

In addition to working with the School of Medicine Faculty Development Office and other groups within UVA medicine, Department of Medicine senior leadership team Vice Chair for Faculty Affairs, Taison Bell, MD has a podcast called “This Medicine Life,”

CLICK TO LISTEN



Margaret Plews-Ogan, MD Presents Webinar Wisdom & Medicine



Margaret Plews-Ogan, MD, Brodie Professor of Medicine, recently presented a webinar, “Wisdom & Medicine,” for the Virtues & Vocations Education for Flourishing: Pursuing Purpose in the Professions webinar series.

CLICK TO WATCH

Listen to Kyle Enfield MD on Society of Critical Care Podcasts (SCCM)



As a guest on the Society’s podcast network, Dr. Enfield discusses a variety of topics such as, vaping and associated respiratory distress syndrome; Clostridium difficile; *Early Palliative Care Consultations in the ICU*, and much more.

CLICK TO LISTEN

Research in Motion

Research in Motion Video: William Petri, MD, PhD

In our new School of Medicine Research in Motion video series, we asked our researchers three questions: What do you do? What do you love about your research? How will it impact human health?

WATCH VIDEO



UVA Health

DIVISION OF HEMATOLOGY & ONCOLOGY

Message from Karen K. Ballen, MD, Hematology & Oncology Division Chief



Karen K. Ballen, MD

The Hematology/Oncology Division has had another fantastic year in clinical care, research, and education. I am so proud of the accomplishments of this wonderful Team, but even more, impressed by the dedication to our patients and each other.

We recruited seven new clinical faculty; four have joined since our last Medicine Matters, and three physicians are arriving shortly: Dr. Mary Helen Witt joined our Augusta Community Oncology practice in May, which has been crucial to expanding our Hematology/Oncology presence in the Valley. Drs. Paul Skelton and Paul Viscuse were recruited to our growing Genitourinary Oncology team this past summer. Dr. John Wagner joined us in December as the Section Head for Stem Cell Transplant/Cell Therapy. In April, Dr. Danny Reed will join our Leukemia Program, and Dr. Balraj Singh will be pioneering our expansion to Prince William Hospital. Finally, Dr. Muneeb Rehman will be a new colleague in August in Gastrointestinal Oncology—many thanks to our Search Committees and Administrative Team for their hard work and excellent job with recruitment.

Congratulations to Jessica Kassay-McAllister and Susie Herndon as our inaugural APP leads. We welcomed Katie Stiebing in GU Oncology, Elizabeth Lester in Infusion, and Kristine Gillis in Cell Therapy in our growing APP program.

And we are so happy to welcome Blake Herring as the Cancer Service Line administrator. Blake is working hard to improve the efficiency of our operations.

The Couric 3rd floor West Clinic, where many of our faculty practice, received for the third consecutive year, the highest honor from Press-Ganey: The 2022 Press Ganey Pinnacle of Excellence Award, based on three years of excellent patient experience results, and the only clinic that has received this award at UVA. We are proud that 26 of our providers were recognized for achieving Press-Ganey scores above the 90th percentile in FY 22. UVA Oncology clinics in Augusta and Pantops and Culpeper all held the coveted number one slot for the University of Virginia Ambulatory clinic.

In basic research, we welcome Dr. Erik Hendrickson and Dr. Anuradha Illendula and their research teams to our Heme/Onc Division. We now have an impressive cadre of basic and translational investigators who are part of our National Cancer Institute Comprehensive Cancer Center led by Dr. Tom Loughran.

We have 197 open clinical research trials in clinical research, of which 20 are investigator-initiated studies. We are also studying and trying to improve access to our clinical trials.

Our division boasts over 6 million dollars in grant support. The grants cover leukemia treatment, novel lymphoma strategies, cell therapy, and lipid signaling. And we are also grateful to many friends of the Cancer Center who provide philanthropic support for our research efforts.

In education, our fellowship program, under the leadership of Drs. Rick Hall and Trish Millard continue to grow in number and national reputation. We had several hundred applications this year for four slots. The fellows have been productive in their clinical work and research, with several presentations at national meetings. Several medical residents are also involved in clinical research projects. Under the direction of Dr. John Densmore, our medical students can complete some of their education in Northern Virginia.

We had a fun spring celebration on the Lawn, and great to see everyone's families. And we enjoyed each other's company at our annual King's Family Polo gathering. We plan a retreat at Morven Farms in May.

It is wonderful to see our Team's accomplishments. Of course, we are most grateful for the opportunity to work with such fantastic colleagues in other divisions and Departments, nurses, research coordinators, division staff, and other team members. You all contribute to making UVA this most special place.

~ Karen K. Ballen, MD, Division Chief

DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates



Robert Dreicer, MD

Medical Oncology

The section of medical oncology has had another productive academic year. Our clinical volumes continue to increase, and our clinical investigative productivity is beginning to rebound from the pre-COVID loss of research personnel in the Cancer Centers' Office of Clinical Research.

At the beginning of the new academic year, the section welcomed two new urologic medical oncologists to the section, Dr. Paul Skelton from the Moffitt Comprehensive Cancer Center in Tampa, FL, and Dr. Paul Viscuse from MD Anderson Cancer Center in Houston, TX. In recognition of his leadership efforts, Dr. Matthew Reilley (GI medical oncology) was named as the initial director of the UVA Cancer Center's Phase I Program. This interdisciplinary program, a "phase I center without walls," is growing rapidly and provides an essential resource to many complex advanced cancer patients referred to the UVA Comprehensive Cancer Center.

~ Robert Dreicer, MD

Melanoma/and related disorders

Drs. Liz Gaughan and Varinder Kaur

APP: Jennifer Eccles Emily Stubbs

Breast Medical Oncology

Drs. Christiana Brenin, Patrick Dillon, and Trish Millard

APP: Paul "Mike" Marshall and Melody Noble

Thoracic Medical Oncology

Drs. Ryan Gentzler and Richard Hall

APP: Marie Thomas

Head and Neck Oncology

Dr. Varinder Kaur

APP: Emily Stubbs

Gastrointestinal Medical Oncology and Unknown Primary Neoplasms

Drs. Tri Le, Paul Kunk, and Matthew Reilley

APP: Jenna Ally and Jenna Campo

Genitourinary Medical Oncology

Drs. Michael Devitt, Robert Dreicer, William Paul Skelton, Paul Viscuse

APP: Jennifer Eccles and Katie Stiebing

Sarcoma

Dr. Michael Douvas

Infusion/Urgent Care

APP: Rachel Crespi and Elizabeth Lester



UVAHealth

DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates

Stem Cell Transplant



John Wagner, MD

The Stem Cell Transplant and Cellular Therapy Program has been in continuous operation for over ten years and has completed over 1000 transplants. We continue to increase our referrals from all over Virginia, including Virginia Beach, Northern Virginia, and Appalachia / SW Virginia. We have two outreach clinics and want to expand our outreach in other areas. We perform transplants for various hematologic malignancies, including plasma cell dyscrasias, non-Hodgkin's lymphoma, Hodgkin lymphoma, acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders, as well as for bone marrow failure states. Our chimeric antigen receptor (CAR) T program continues to grow, and we have both FDA-approved and research CAR T in lymphoma, myeloma, and leukemia. We are a core center with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to open cooperative group clinical trials at UVA for our patients.

We were well represented at the recent Transplant and Cellular Therapy meetings, with several presentations by our trainees and faculty.

~John Wagner, MD

Stem Cell Transplant

Drs. Karen Ballen, Indumathy Varadarajan, Leonid Volodin and John Wagner

APP: Hania Bushnaq-Aloul, Jessica Kassay-McAllister, and Christine Mazimba

APP Inpatient: Isabel Burgess, Mary Faith Dudley, Kristine Gillis, Josh Humphrey, and Erin Harr

Hematologic Malignancies

The Hematologic Malignancy Program continues to grow in both inpatient and outpatient care. Drs. Ayers, Marchi, Portell, and Williams have had several presentations on lymphoma at international conferences, and we have several clinical trials in both B-cell and T-cell lymphoma. Dr. Keng has expanded our quality program and is a global figure in cancer quality and serving as inpatient Medical Director. Dr. El Chaer has had several international presentations and is the Medical Director of Infusion. Dr. Douvas focuses on the complex young adult population and has open investigator-initiated trials for leukemia. Dr. Garrett-Bakelman is studying epigenetics and older patients with Acute Myeloid Leukemia. In myeloma, Drs. Densmore and Foster are focusing on novel strategies for this population, with so many new treatment options for these patients, including cellular-based therapy.

~Karen Ballen, MD

Lymphoma and CLL

Drs. Emily Ayers, Enrica Marchi, Craig Portell, and Michael E. Williams

APP: Kim Conrad and Tammy Tedsen

Myeloma

Drs. John Densmore and Laahn Foster

Leukemia

Drs. Michael Douvas, Firas El Chaer, Francine Garrett-Bakelman, Michael Keng, and Daniel Reed

APP: Kim Conrad and Amelia Hodson



UVAHealth

DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates



Kelly Davidson, MD

was recently awarded a Virginia Department of Health grant to support this work. She and colleagues in cardiothoracic surgery have created a perioperative anemia program to improve anemia management and reduce the transfusion burden in cardiothoracic surgery patients.

The section looks forward to adding two new physicians to our group in the coming year.

~*Kelly Davidson, MD*

Classical Hematology

Drs. Kelly Davidson, Valery Kogler, Hillary Maitland, and Louise Man
APP: Julie Armatas and Katie Gabler

Classical Hematology

The classical hematology team has had a very active year, managing patients in outpatient and inpatient settings who require complex, well-coordinated care for various complex blood disorders. We are excited to welcome Dr. Valery Kogler, who has recently joined the UVA Department of Pathology as a Blood Bank physician. She has a second appointment in Hematology and will be attending inpatient hematology consults.

Dr. Louise Man continues to lead our Adult Comprehensive Hemophilia Center, a grant-supported collaborative effort with Pediatric Hematology. She leads a bimonthly multidisciplinary Thrombosis Conference with colleagues in Vascular Medicine and Interventional Radiology. She is working on bringing clinical trials to UVA for rare hemostasis disorders, including acquired hemophilia. Dr. Maitland is developing a mobility pilot in the bariatric population to improve pre-operative education and institute a walking program to reduce the risk for VTE. Dr. Kelly Davidson leads our Adult Sickle Cell Disorders Program, which



Adult Sickle Cell Team: Jennifer Golden, Leslie Ward, Kelsey Lederman, Katie Gabler, & Kelly Davidson

DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates



Elizabeth Gaughan, MD

UVA Community Oncology

The UVA Community Oncology Section includes five physicians and three advanced practice providers serving patients with the spectrum of hematologic and solid tumor diagnoses in Fishersville, Pantops, and Culpeper. Our Team oversees the multidisciplinary infusion centers at each location. The last year has seen rapid growth of clinical volumes, investments in staff expansion to maximize the use of existing space, and further alignment and integration between the community practices, medical center teams, and the academic division. Our success in maintaining patient access for both clinic and infusion results from patient-focused teamwork, incorporation of technology, innovative problem solving, and strong relationships within the Oncology service line.

This year's major focus areas include managing our program's growth and optimizing the hub-and-spoke relationship between the academic and community providers. Space expansion in both Pantops and Augusta is in

the planning phase. Our Culpeper practice is the hub of cancer service for our Northern Virginia patients. Construction is underway on a vault to house the new linear accelerator at the Culpeper Medical Center.

Our experience with aligning and integrating our community and academic teams will be critical to the successful expansion of UVA Oncology into Prince William and Haymarket communities. In March 2023, we will welcome Dr. Balraj Singh, MD, to our Community Oncology team. Dr. Singh, Dr. Patel, and Dr. Mahjoub will lead our expansion into these new markets.

~Elizabeth Gaughan, MD

Augusta Location

Drs. Gwenalyn Garcia, Nicholas Paphitis, and Mary Helen Witt

APP: Meera Kumar

Culpeper Location

Drs. Ali Mahjoub, Pranav Patel, and Balraj Singh

APP: Michelle Otto

Charlottesville/Pantops Location

APP: Susie Herndon

Gainesville Location

Drs. Ali Mahjoub, Pranav Patel, and Balraj Singh



UVAHealth

DIVISION OF HEMATOLOGY & ONCOLOGY

Clinical Updates

Advance Practice Providers

Our Oncology APP teams spent this past year leading the implementation of the APP Optimization/Utilization project. In March 2022, Susie Herndon, NP, joined Jess Kassay-McAllister NP, and Bill Lombardi, DNP, as the first APP Supervisor Leads for the division. Over the last year, the group has worked with Chartis Consulting and a multidisciplinary committee of APPs, physicians, and administrators to improve APP utilization across the pilot oncology teams to allow APPs at UVA to work to their full scope of practice. The initial workgroup teams identified and reduced barriers to APPs' autonomous practice and optimization by partnering with physician colleagues to develop independent templates with 6-8 sessions and an 80% template utilization rate goal. Optimization work is ongoing in Oncology, and the new Center for Advanced Practice (CAP) will use the knowledge gained to advance the work across the health system.

We would like to highlight Christine Mazimba, DNP, and her research abstract titled, The Impact of Social Vulnerability Index on Survival Following Autologous Stem Cell Transplant for Multiple Myeloma, which was accepted for oral presentation at the Transplant Cellular Therapy (TCT) Conference this past February 2023. We also would like to highlight Jenna Ally and Jenna Campo, who won a travel grant for allied health professionals to the NANETs conference we attended in October.

~ Jess Kassay-McAllister and Susie Herndon, APP Supervisors

Clinical Volume Chart FY 2020 - FY 2022

	FY 2020	FY 2021	FY 2022
Inpatient Attending	13,351	14,182	14,066
Inpatient Consults	2,700	2,733	2,546
Inpatient Totals	16,051	16,915	16,612
Outpatient New and Consults	4,125	4,611	5,257
Established Outpatient Visits	40,721	43,876	47,646
Outpatient Totals	48,487	48,487	52,903

2022 Clinical Faculty Promotions



Dr. Varinder Kaur was promoted to Associate Professor



Dr. Tri M. Le was promoted to Associate Professor

DIVISION OF HEMATOLOGY & ONCOLOGY

Clinical Updates

Pinnacle of Excellence Award Presentation

We are proud to announce that the Emily Couric Hematology/Oncology West Clinic is the proud recipient of the Pinnacle of Excellence Award for the third straight year. This prestigious award is a reflection of their remarkable work and unwavering commitment to our mission of Transforming health and inspiring hope for all Virginians and beyond.

The Team has been recognized for exhibiting and consistently maintaining the highest standards in the Patient Experience category over three years. This is the third year and the only clinic at UVA Health to earn this recognition.



UVA Breast Care Program

It has been a little over two years since the Breast Care Program moved to 652 Peter Jefferson Parkway. The 18,500 sq. ft site has been well received by patients and staff alike, with a full complement of providers and staff covering the disciplines of radiology, plastics, and oncologic surgical clinics, medical oncology, infusion center, PM&R, Physical therapy, massage therapy, an on-site Flourish “feel better” boutique, as well as genetics and survivorship care services. We now have four breast surgeons, three plastic surgeons, three medical oncologists, as well as 4 APPs providing care to our patients. Through the support of our APPs, we are developing an integrated Survivorship Care Clinic to accommodate our ever-growing long-term survivors!

The center will soon expand to include the 3rd floor of the building, bringing in additional Cancer Service Line services and providers, an on-site investigational pharmacy, a full lab, and 40 infusion bays. ETA Q4 2024.

After a hiatus during the Covid-19 pandemic, the Breast Center’s Sunshine Committee is back! The committee meets monthly to plan events and activities for staff, including holiday potlucks and celebrations for milestones and birthdays. The committee also supports staff in times of need and bereavement. More recently, staff members celebrated Valentine’s Day by writing positive messages to co-workers on hearts that were displayed in the break room. The committee is looking forward to planning an all-staff picnic on-site to kick off the summer months. (16)

DIVISION OF HEMATOLOGY & ONCOLOGY

Clinical Updates

UVA Breast Care Program

And our Team is growing fast! We have several new additions to our Breast Center Family:



Madeleine Beard was born August 31, 2022 to Sarah and Ethan Beard. Sarah is our new Surgical Oncology APP



Everett Hans Millard was born November 21, 2022, to Drs. Trish and Alex Millard. He is growing and happy. He gives the best smiles to his sister (Leighton) and brother (Graham).



Kai Rohan Swarr was born October 22, 2022 to Nayanika Basu (Clinical Pharmacist) and her husband Tim Swarr. He enjoys playing in his jumper, smiling at everyone he meets, and rolling over onto his belly from his back!

DIVISION OF HEMATOLOGY & ONCOLOGY

Educational Updates

Message from the Program Director

Serving as the UVA hematology / oncology fellowship program director is a great honor. Our fellowship program is comprised of outstanding physicians who choose to train with us in Charlottesville and immerse themselves in our rich clinical and research programs across the UVA Comprehensive Cancer Center.

This year we welcomed four new fellows into our program – Jeffrey Lantz, DO, who joined us from Wake Forest University, Jack Masur, MD, who joined us from the University of Maryland; and Shipra Maheshwari, MD, and Jenna Schlefman, MD, who joined us from UVA. All four first-year fellows have done an excellent job assimilating into the program and diving into our clinical and research programs.

Beginning in July 2023, our fellowship program will have 12 fellows for the first time in our history. We successfully matched four new fellows into our program in December 2022 from among over 430 applicants. Fabian Bolte MD and Sean Dougherty MD will join us from our UVA internal medicine program, Gautham Prakash MD from Rush University, and Valerie Tran MD from Virginia Commonwealth University. As in years past, we were thrilled with our match and look forward to welcoming our new fellows in the coming months.

Later this year, we will celebrate three fellows graduating from our program. Sam, Nick, and Eric have tremendously contributed to our fellowship program over the past three years. We look forward to celebrating their accomplishments at our graduation ceremony in May.

~ Richard Hall, MD

2023 Graduating Fellows

Samantha DiBenedetto, MD

Sam has been our chief fellow over the past year. She is known not only for being an accomplished equestrian rider and new mom but she is widely respected for her outstanding clinical care and genuine love of her work. Sam is joining Virginia Cancer Specialists in Fairfax, VA, later this summer.

Eric Pierce, MD

Eric has been a pleasure to know and work with over the past three years but also before that as a resident at UVA. He is unflappable and has a calm confidence that we greatly admire. Eric is joining Blue Ridge Cancer Care in Roanoke, VA, later this summer.

Nick Schmidt, MD

Nick has likewise been lauded for his outstanding clinical care throughout his training and his love of all things caffeinated (especially the fellow's office Keurig machine). Nick will join a practice in Charleston, SC, after graduation this summer.



3rd Year Fellows
Eric Pierce, Sam DiBenedetto, & Nick Schmidt



2ND Year Fellows
Drs. Philip Young, John Thomas, Chris Thomas,
& Nathan Roberts



Hematology/Oncology Fellows with Director Dr. Rick Hall

DIVISION OF HEMATOLOGY & ONCOLOGY

Research Updates

Research funding data:

ALL RESEARCH AWARDS	
FY 2021 \$7,107,000	FY 2022 \$8,460,587

Hematology/Oncology faculty serve as PIs on 197 active protocols. Selected examples across the disease teams are as follows:

Cellular Therapies

IRB # 15670A *Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications*

Sponsor Protocol 10-CBA Unlicensed CVU Sponsor National Marrow Donor Program (NMDP)

CT. Gov. ID: NCT01351545

Principal Investigator: Ballen, Karen

Study Contact: Danyelle Coley: jcs6rz@virginia.edu - 434-982-5027

IRB # A Phase 1/2, Open-Label, First-in-Human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects with CD5+ Relapsed/Refractory Peripheral T Cell Lymphoma

HSR210357 Sponsor Protocol MTX-TCL-001 Sponsor Myeloid Therapeutics

CT. Gov. ID: NCT05138458

Principal Investigator: Marchi, Enrica

Study Contact: Jungeun Kim jk9te@virginia.edu - 434-982-3365

IRB # Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Viralym-M Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant

HSR210040 Sponsor Protocol P-105-202 Sponsor AlloVir Kirby Grove

CT. Gov. ID: NCT04693637

Principal Investigator: Varadarajan, Indumathy

Study Contact: Sara Casana Granell qna7wg@virginia.edu - 434-924-5254

IRB # A Phase 2/3, Multicenter, randomized, Double-blind, placebo-controlled, study to evaluate the safety and efficacy of Alpha-1 Antitrypsin for the prevention of graft-versus host disease in patients receiving hematopoietic cell transplant

HSR220016 (MODULAATE Study)

Sponsor Protocol CSL964_2001 Sponsor CSL Behring, LLC

CT. Gov. ID: NCT03805789

Principal Investigator: Volodin, Leonid Study

Contact: Danyelle Coley jcs6rz@virginia.edu - 434-982-5027

HEMATOLOGY/ONCOLOGY GRAND ROUNDS

First Wednesday each Month, 8 - 9am
Via Zoom

DIVISION OF HEMATOLOGY & ONCOLOGY

Research Updates

LCM: Lymphoma/CLL/Myeloma

IRB # *A phase 3 randomized study comparing bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacebtogene autoleucel, a chimeric antigen receptor T cell (CAR-T) Therapy directed against CMA versus bortezomib, lenalidomide, and dexamethasone (VRd) followed by lenalidomide and dexamethasone (RD therapy in patients with newly diagnosed multiple myeloma for who hematopoietic stem cell transplant is not planned as initial therapy*

HSR220093 Sponsor Protocol 68284528MMY3004

Sponsor: Janssen Research & Development

CT. Gov. ID: NCT04923893

Principal Investigator: Foster, Laahn

Study Contact: Sara Casana Granell qna7wg@virginia.edu - 434-924-5254

IRB # *20317 A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission*

Sponsor Protocol: EA4151

Sponsor: ECOG

CT. Gov. ID: NCT03267433

Principal Investigator: Portell, Craig

Study Contact: Erica Stallard elg9r@virginia.edu - 434-243-2649

IRB # *A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia*

HSR200173 Sponsor Protocol: TAK-079-1004

Sponsor: Millennium

CT. Gov. ID: NCT04278924

Principal Investigator: Davidson, Kelly

Study Contact: Tiffany Tolley tt4ek@virginia.edu - 434-243-2243

IRB # *A phase Ib open-label study to evaluate the safety and anti-cancer activity of loncastuximab terisine in combination with other anti-cancer agents in patients with relapsed ore refractory B-cell non-Hodgkin lymphoma*

HSR220009 Sponsor Protocol: ADCT-402-105

Sponsor: ADC Therapeutics S.A.

CT. Gov. ID: NCT04970901

Principal Investigator: Ayers, Emily

Study Contact: Michal Ande mma2cz@virginia.edu - 434-297-5150

Breast

IRB # *19406A Phase I/II Study of Anti-CD3xAnti-HER2/neu (HER2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women with Metastatic Breast Cancer*

Sponsor Protocol: Breast 47 BATs

Sponsor: University of Virginia

CT. Gov. ID: NCT03272334

Principal Investigator: Dillon, Patrick

Study Contact: Ashley Donihee zwz6jm@virginia.edu - 434-243-6377

IRB # *22040 Pre-Operative Window of Adjuvant Endocrine Therapy to Inform Radiation Therapy Decisions in Older Women with Early-Stage Breast Cancer*

Sponsor Protocol: Power

Sponsor: University of Virginia

CT. Gov. ID: NCT04272801

Principal Investigator: Millard, Trish

Study Contact: Meagan Gonyar mtd6wa@virginia.edu

Olena Glushakova oyg2n@virginia.edu - 434-982-6584

DIVISION OF HEMATOLOGY & ONCOLOGY

Research Updates

CALM: Chronic & Acute Leukemia/MDS & MPN

IRB # 21417 Phase I Study of Inotuzumab Ozogamicin with 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Younger Adults Ages 18-55 with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor Protocol: ALL-001 Funded by Pfizer

Sponsor: University of Virginia

CT. Gov. ID: NCT03962465

Principal Investigator: Douvas, Michael

Study Contact: Cara Hanby clh5ke@virginia.edu - 434-243-9900

Cory Caldwell cjc2p@virginia.edu - 434-297-4182

IRB # 21188 Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

Sponsor Protocol: ARO-021

Sponsor: AROG Pharmaceuticals, Inc.

CT. Gov. ID: NCT03258931

Principal Investigator: Keng, Michael

Study Contact: Kelly Reed yvy8ge@virginia.edu - 434-297-7783

IRB # A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

HSR200064 Sponsor Protocol BBI-TP-3654-102

Sponsor: Sumitomo Pharma Oncology Inc.

CT. Gov. ID: NCT04176198

Principal Investigator: El Chaer, Firas

Study Contact: Kelly Reed yvy8ge@virginia.edu - 434-297-7783

Developmental Therapeutics

IRB # 21491 A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)

Sponsor Protocol: XmAb23104

Sponsor: Xencor, Inc.

CT. Gov. ID: NCT03752398

Principal Investigator: Reilley, Matthew

Study Contact: DeJuana Coleman evq9yw@virginia.edu - 434-924-9199

IRB # A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

HSR210282 Sponsor Protocol: XL092-001

Sponsor: EXELIXIS, Inc.

CT. Gov. ID: NCT03845166

Principal Investigator: Dreicer, Robert

Study Contact: Alexandra Cash aec5gn@virginia.edu - 434-243-4305

Gastro-intestinal (GI)

IRB # 19236 Phase Ib/II Treatment of Advanced Pancreatic Cancer with anti-CD3 x anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)

Sponsor Protocol: BATS PANCREAS

Sponsor: University of Virginia

CT. Gov. ID: NCT03269526

Principal Investigator: Le, Tri

Study Contact: Ashley Donihee zwz6jm@virginia.edu - 434-243-6377

DIVISION OF HEMATOLOGY & ONCOLOGY

Research Updates

Gastro-intestinal (GI)

IRB # *A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers*

HSR210423 Sponsor Protocol: 10476

Sponsor: ETCTN

CT. Gov. ID: NCT04941287

Principal Investigator: Kunk, Paul

Study Contact: Cecilia Flanagan cnr7zp@virginia.edu

GenitoUrinary (GU)

IRB # *21826A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair*

Sponsor Protocol: C18-205

Sponsor: Memorial Sloan-Kettering Cancer Center

CT. Gov. ID: NCT04019327

Principal Investigator: Devitt, Michael

Study Contact: Alexandra Cash aec5gn@virginia.edu - 434-243-4305

Head & Neck

IRB # *20516 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)*

Sponsor Protocol: 689-00

Sponsor: Merck Sharp & Dohme Corp.

CT. Gov. ID: NCT03765918

Principal Investigator: Kaur, Varinder

Study Contact: Olusegun Adelaja oba4e@virginia.edu

Melanoma

IRB # *17700A trial to evaluate the safety and immunogenicity of a helper peptide vaccine plus combination of BRAF inhibition and MEK inhibition (Mel61)*

Sponsor Protocol: MEL 61

Sponsor: NCI

CT. Gov. ID: NCT02382549

Principal Investigator: Gaughan, Elizabeth

Study Contact: Not specified

Thoracic

IRB # *A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)*

HSR220031 Sponsor Protocol: D9078C00001

Sponsor: AstraZeneca

CT. Gov. ID: NCT05221840

Principal Investigator: Gentzler, Ryan

Study Contact: Gracie Hockenberry mgt4n@virginia.edu - 434-297-7784

IRB # *17721 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein*

Sponsor Protocol: E4512

Sponsor: ECOG-ACRIN

CT. Gov. ID: NCT02201992

Principal Investigator: Hall, Richard

Study Contact: Gracie Hockenberry mgt4n@virginia.edu - 434-297-7784

DIVISION OF HEMATOLOGY & ONCOLOGY

Recent Events


Hematology/Oncology Spring Celebration The Colonnade Club June 1, 2022



DIVISION OF HEMATOLOGY & ONCOLOGY

Recent Events

American Society of Clinical Oncology Annual Meeting June 3-7, 2022 in Chicago, Illinois




Sam DiBenedetto and Dr. Rick Hall




Drs. Paul Skelton, Ryan Gentzler, Matt Reilley, Mike Devitt, Paul Viscuse, Sam DiBenedetto, & Rick Hall

San Antonio Breast Cancer Symposium 2022 December 6-10, 2022 in San Antonio, Texas



Dr. Patrick Dillon



Dr. Christiana Brenin



Drs. Christiana Brenin & David Brenin

DIVISION OF HEMATOLOGY & ONCOLOGY

Recent Events


The 64th American Society of Hematology Annual Meeting 2022 December 10-13 in New Orleans, Louisiana




Dr. Emily Ayers




Drs. Firas El Chaer, Kiarash Salafian, Nathan Roberts & Michael E. Williams



Drs. Firas El Chaer, Daniel Reed & Michael Keng



Dr. Kiarash Salafian



Dr. Nathan Roberts

DIVISION OF HEMATOLOGY & ONCOLOGY

Recent Events

1,000 Stem Cell Transplant

[Read More](#)



Drs. John Wagner, Brian Wispelway, Leonid Volodin, Michael E. Williams, Mitch Rosner, Karen Ballen, & Firas El Chaer

ASCO Gastrointestinal Cancers Symposium

January 19-21, 2023 in San Francisco, California



Dr. Einsley Janowski, Dr. Paul Kunk, Jenna Campo, APP and Jenna Ally, APP


DIVISION OF HEMATOLOGY & ONCOLOGY

Recent Events

Transplantation & Cellular Therapy Meeting February 15-19, 2023 in Orlando, Florida



Firas El Chaer, Jess Kassay-McAllister, Leonid Volodin, Kathy DeGregory, & Jeremy Sen



Dr. Karen Ballen



Kiarash Salafian, Brooke Henry, Judy Kauffman, Firas El Chaer, Indu Varadarajan, Jess Kassay-McAllister, Nick Lucchesi




Viktoriya Zelikson, Brooke Henry, Judy Kauffman, Kiarash Salafian, Carly Grubbs, & Nick Lucchesi

ASCO GU Meeting February 16-18, 2023 in San Francisco, California



Drs. Paul Viscuse and Paul Skelton



Dr. Paul Viscuse



Drs. Paul Viscuse, Chris Luminais & Paul Skelton

Recent Events



School of Medicine Awards

2022 the University of Virginia School of Medicine Master Clinician Award Dr. Michael E. Williams

“He is a person of the utmost integrity, a role model for trainees and colleagues. He is the go-to doctor for lymphoma in Virginia and nationwide. He demonstrates an innate kindness and generosity in almost every interaction and remains calm under pressure.” – Colleague

“There is not a single practice in oncology throughout the Commonwealth that does not know and love Mike Williams. He is incredibly well respected for his care and sought after on a nearly daily basis for his consultation and expertise.” – Colleague

“He made us feel like he was personally invested in my journey, and we felt so blessed to be under Dr. Mike’s care. One thing we learned during those first few months was that Dr. Williams was a well-respected physician; all the fellows, residents, and nurses on Dr. Mike’s Team followed his example by treating us with the utmost kindness and respect.” – Patient

2022 Graduate Medical Education Excellence in Mentorship Award Dr. Firas El Chaer

“He nearly always has a trainee with him, who he incorporates into his workflow seamlessly. Dr. El Chaer is full of energy and carries an enthusiasm for teaching which is contagious within the room.” – Colleague

“As a clinical researcher, Dr. El Chaer is an excellent model for trainees interested in pursuing academic medicine. He is constantly brainstorming new projects and is always looking to include fellows in his work, so much so that it is rare to find a fellow who is not working on a project with him.” – Trainee

“Dr. El Chaer has helped to give meaningful substance and structure to resident education. His approach embodies a modern and creative interpretation of what house staff education should be, creating joy in expression and acquisition of knowledge and providing the conditions for organic learning.” – Trainee

Administration News



Jeffrey Ware, Finance Administrator, Retirement

After putting in an incredible 37 years with the University of Virginia and eleven years with the Division of Hematology and Oncology, Jeff Ware reached another milestone, retirement, on January 15, 2023.

When Jeff joined the division of Hematology and Oncology eleven years ago, the division was a quarter of its current size, which now employs more than 40 faculty and 27 APPs.

Jeff has genuinely earned this time to embark on a new journey, and we wish him and his family all the best. We greeted Jeff's retirement with some sadness, but we are also happy for Jeff, who can now enjoy his own time.

Some of Jeff's new plans include traveling with his wife and family in their new camper across the country.

We thank Jeff for his many contributions to HemOnc over the past decade. On behalf of everyone in HemOnc, we wish him the best of luck!

~ Rachael Boston, Division Administrator

Welcome Matthew Sellman

Matthew Sellman joined Hematology/Oncology on November 21, 2022 as the Sr. Finance Generalist. Matt worked with Jeff to ensure a smooth transition prior to Jeff's retirement. We are delighted that Matt has joined our team.



UVA Health

2023 Updates in Hematology and Hematologic Malignancies

April 14, 2023

Charlottesville Omni Hotel

212 Ridge McIntire Road, Charlottesville

This program will explore research and advances in the diagnosis and management of benign hematologic conditions and hematologic malignancies, including indications for novel therapies and use in special populations.

More information at www.cmevillage.com

PUBLICATIONS (Total number of publications in 2022-2023: 135)

Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. Ung J, Tan SE, Fox TE, Shaw JJP, Vass LR, Costa-Pinheiro P, **Garrett-Bakelman FE, Keng MK**, Sharma A, Claxton DE, Levine RL, Tallman MS, Cabot MC, Kester M, **Feith DJ, Loughran TP Jr.** Blood Rev. 2022 Sep;55:100950. doi: 10.1016/j.blre.2022.100950. Epub 2022 Apr 9. PMID: 35487785 Review.

Variant Acute Promyelocytic Leukemia Presenting Without Auer Rods Highlights the Need for Correlation with Cytogenetic Data in Leukemia Diagnosis. Courville EL, Shantzer L, Vitzthum von Eckstaedt HC, Mellot H, **Keng M**, Sen J, Morris A, Williams E, **El Chaer F.** Lab Med. 2022 Jan 6;53(1):95-99. doi: 10.1093/labmed/lmab051. PMID: 34268555

Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. **Varadarajan I**, Pierce E, Scheuing L, Morris A, **El Chaer F, Keng M.** Onco Targets Ther. 2023 Jan 14;16:1-16. doi: 10.2147/OTT.S274551. eCollection 2023. PMID: 36685611 Review.

Reducing Repeat Blood Cultures in Febrile Neutropenia: A Single-Center Experience. Robinson ED, **Keng MK**, Thomas TD, Cox HL, Park SC, Mathers AJ. Open Forum Infect Dis. 2022 Oct 14;9(11):ofac521. doi: 10.1093/ofid/ofac521. eCollection 2022 Nov. PMID: 36408469

Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Garcia JS, Flamand Y, Penter L, **Keng M**, Tomlinson B, Mendez LM, Koller PB, Cullen N, Arihara Y, Pfaff KL, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler CS, Ho VT, Jonas BA, Lusk MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ. Blood. 2022 Nov 4;blood.2022017686. doi: 10.1182/blood.2022017686. Online ahead of print. PMID: 36332187 No abstract available.

MRD in ALL: Optimization and Innovations. Pierce E, Mautner B, Mort J, Blewett A, Morris A, **Keng M, El Chaer F.** Curr Hematol Malig Rep. 2022 Aug;17(4):69-81. doi: 10.1007/s11899-022-00664-6. Epub 2022 May 26. PMID: 35616771 Review.

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). Vavolizza RD, Petroni GR, Mauldin IS, Chianese-Bullock KA, Olson WC, Smith KT, Dengel LT, Haden K, Grosh WW, **Kaur V**, Varhegyi N, **Gaughan EM**, Slingluff CL Jr. J Immunother Cancer. 2022 Sep;10(9):e005424. doi: 10.1136/jitc-2022-005424. PMID: 36100309 Clinical Trial.

Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability. Wray JP, Deltcheva EM, Boiers C, Richardson SE, Chhetri JB, Brown J, Gargic S, Guo Y, **Illendula A**, Martens JHA, Stunnenberg HG, Bushweller JH, Nimmo R, Enver T. Nat Commun. 2022 Nov 21;13(1):7124. doi: 10.1038/s41467-022-34653-3. PMID: 36411286

A nano-enhanced vaccine for metastatic melanoma immunotherapy. Salotto KE, Olson WC Jr, Pollack KE, **Illendula A**, Michel E, Henriques S, Fox T, Walker S, Dunlap-Brown M, Slingluff CL Jr, Kester M, Snyder HW. Cancer Drug Resist. 2022 Jul 7;5(3):829-845. doi: 10.20517/cdr.2021.132. eCollection 2022. PMID: 36176766

Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer. Qi X, Wu F, Kim SH, Kaifi JT, Kimchi ET, Snyder H, **Illendula A**, Fox T, Kester M, Staveley-O'Carroll KE, Li G. FASEB J. 2022 Apr;36(4):e22250. doi: 10.1096/fj.202101707R. PMID: 35294071

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, **Illendula A**, Krämer OH, Schick M, Wolf E, van IJcken WFJ, Esposito I, Keller U, Schneider G, Wirth M. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2105691119. doi: 10.1073/pnas.2105691119. PMID: 35197278

Shantzer, L. B., Dougherty, S. C., Bolte, F., Melson, J. W., Reed, D. R., Lynch, A. C., . . . **Hall, R. D.** (2023). Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report.. Clin Lung Cancer, 24(2), e60-e64. doi:10.1016/j.clcc.2022.11.006

Replicative Instability Drives Cancer Progression. Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, **Dillon PM**, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VE, Akerley WL, **Gentzler RD, Hall RD**, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW. Biomolecules. 2022 Oct 26;12(11):1570. doi: 10.3390/biom12111570. PMID: 36358918

Bolte, F. J., McTavish, S., Wakefield, N., Shantzer, L., Hubbard, C., Krishnaraj, A., . . . **Hall, R. D.** (2022). Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy.. Front Oncol, 12, 986236. doi:10.3389/fonc.2022.986236

PUBLICATIONS

Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, Bolanos LC, Christie S, Smith MA, Niederkorn M, Muto T, Kesari S, **Garrett-Bakelman FE**, Bartholdy B, Will B, Weirauch MT, Mulloy JC, Gul Z, Medlin S, Kovall RA, Melnick AM, Perentesis JP, Greis KD, Nurmammedov E, Seibel WL, Starczynowski DT. *Sci Transl Med.* 2022 Mar 9;14(635):eabb7695. doi: 10.1126/scitranslmed.abb7695. Epub 2022 Mar 9. PMID: 35263148

Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. Ung J, Tan SE, Fox TE, Shaw JJP, Vass LR, Costa-Pinheiro P, **Garrett-Bakelman FE**, **Keng MK**, Sharma A, Claxton DF, Levine RL, Tallman MS, Cabot MC, Kester M, **Feith DJ**, **Loughran TP Jr.** *Blood Rev.* 2022 Sep;55:100950. doi: 10.1016/j.blre.2022.100950. Epub 2022 Apr 9. PMID: 35487785 Review.

Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13. Prajapati SC, Dunham N, Fan H, **Garrett-Bakelman FE**. *Biotechniques.* 2022 Mar;72(3):81-84. doi: 10.2144/btn-2021-0089. Epub 2022 Feb 4. PMID: 35119307

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. Rapaport F, Seier K, Neelamraju Y, Hassane D, Baslan T, Gildea DT, Haddox S, Lee T, Murdock HM, Sheridan C, Thurmond A, Wang L, Carroll M, Cripe LD, Fernandez H, Mason CE, Paietta E, Roboz GJ, Sun Z, Tallman MS, Zhang Y, Gönen M, Levine R, Melnick AM, Kleppe M, **Garrett-Bakelman FE**. *Blood Cancer J.* 2022 Sep 23;12(9):137. doi: 10.1038/s41408-022-00736-z. PMID: 36151075

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, **Gentzler RD**, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephens KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazebe AM, Hodi FS. *Lancet Oncol.* 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. PMID: 35033226 Clinical Trial.

Replicative Instability Drives Cancer Progression. Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, **Dillon PM**, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, **Gentzler RD**, **Hall RD**, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW. *Biomolecules.* 2022 Oct 26;12(11):1570. doi: 10.3390/biom12111570. PMID: 36358918

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. Bolte FJ, McTavish S, Wakefield N, Shantzer L, Hubbard C, Krishnaraj A, Novicoff W, **Gentzler RD**, **Hall RD**. *Front Oncol.* 2022 Sep 23;12:986236. doi: 10.3389/fonc.2022.986236. eCollection 2022. PMID: 36212442

A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. Ardeshtir-Larijani F, Althouse SK, Leal T, Feldman LE, Hejleh TA, Patel M, **Gentzler RD**, Miller AR, Hanna NH. *Clin Lung Cancer.* 2022 Nov;23(7):578-584. doi: 10.1016/j.clcc.2022.07.001. Epub 2022 Jul 21. PMID: 36041949 Clinical Trial.

Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report. Shantzer LB, Dougherty SC, Bolte F, Melson JW, Reed DR, Lynch AC, **Gentzler RD**, Novicoff W, **Hall RD**. *Clin Lung Cancer.* 2023 Mar;24(2):e60-e64. doi: 10.1016/j.clcc.2022.11.006. Epub 2022 Nov 26. PMID: 36526550 No abstract available.

Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice. Rhodin KE, **Gaughan EM**, Raman V, Salama AK, Hanks BA, Shah R, Tyler DS, Slingluff CL Jr, Beasley GM. *Ann Surg.* 2022 Jul 7;10.1097/SLA.0000000000005459. doi: 10.1097/SLA.0000000000005459. Online ahead of print. PMID: 35797609

Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series. **Gaughan EM**, Horton BJ. *Front Oncol.* 2022 Apr 28;12:855782. doi: 10.3389/fonc.2022.855782. eCollection 2022. PMID: 35574303

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). Vavolizza RD, Petroni GR, Mauldin IS, Chianese-Bullock KA, Olson WC, Smith KT, Dengel LT, Haden K, Grosh WW, **Kaur V**, Varhegyi N, **Gaughan EM**, Slingluff CL Jr. *J Immunother Cancer.* 2022 Sep;10(9):e005424. doi: 10.1136/jitc-2022-005424. PMID: 36100309 Clinical Trial.

PUBLICATIONS

Multiple evanescent white dot syndrome-like reaction associated with ipilimumab and nivolumab immune checkpoint inhibitor therapy for metastasis of choroidal melanoma. Duong RT, Ambati NR, Peddada KV, Elghawy O, **Gaughan EM**, Shildkrot Y. Am J Ophthalmol Case Rep. 2022 Jan 31;25:101351. doi: 10.1016/j.ajoc.2022.101351. eCollection 2022 Mar. PMID: 35243137

PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy. Griesinger L, Nyarko-Odoom A, Martinez SA, Shen NW, Ring KL, **Gaughan EM**, Mills AM. Appl Immunohistochem Mol Morphol. 2023 Feb 22. doi: 10.1097/PAI.0000000000001108. Online ahead of print. PMID: 36812389

Genomic landscape of TCR $\alpha\beta$ and TCR $\gamma\delta$ T-large granular lymphocyte leukemia. Cheon H, Xing JC, Moosic KB, Ung J, Chan VW, Chung DS, Toro ME, Elghawy O, Wang JS, Hamele CE, Hardison RC, Olson TL, Tan SE, **Feith DJ**, Ratan A, **Loughran TP**. Blood. 2022 May 19;139(20):3058-3072. doi: 10.1182/blood.2021013164. PMID: 35015834

CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk. Baer C, Kimura S, Rana MS, Kleist AB, Flerlage T, **Feith DJ**, Chockley P, Walter W, Meggendorfer M, Olson TL, Cheon H, Olson KC, Ratan A, Mueller ML, Foran JM, Janke LJ, Qu C, Porter SN, Pruett-Miller SM, Kalathur RC, Haferlach C, Kern W, Paietta E, Thomas PG, Babu MM, **Loughran TP Jr**, Iacobucci I, Haferlach T, Mullighan CG. Nat Genet. 2022 May;54(5):637-648. doi: 10.1038/s41588-022-01059-2. Epub 2022 May 5. PMID: 35513723

Intersection Between Large Granular Lymphocyte Leukemia and Rheumatoid Arthritis. Moosic KB, Ananth K, Andrade F, **Feith DJ**, Darrah E, **Loughran TP Jr**. Front Oncol. 2022 May 13;12:869205. doi: 10.3389/fonc.2022.869205. eCollection 2022. PMID: 35646651 Review.

Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. Ung J, Tan SE, Fox TE, Shaw JJP, Vass LR, Costa-Pinheiro P, **Garrett-Bakelman FE**, **Keng MK**, Sharma A, Claxton DE, Levine RL, Tallman MS, Cabot MC, Kester M, **Feith DJ**, **Loughran TP Jr**. Blood Rev. 2022 Sep;55:100950. doi: 10.1016/j.blre.2022.100950. Epub 2022 Apr 9. PMID: 35487785 Review.

LGL leukemia patients exhibit substantial protective humoral responses following SARS-CoV-2 vaccination. Cheon H, Elghawy O, Shemo BC, **Feith DJ**, **Loughran TP Jr**. EJHaem. 2022 May 31;3(3):919-923. doi: 10.1002/jha2.472. eCollection 2022 Aug. PMID: 35941882

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. Khokhlatchev AV, Sharma A, Deering TG, Shaw JJP, Costa-Pinheiro P, Golla U, Annageldiyev C, Cabot MC, Conaway MR, Tan SE, Ung J, **Feith DJ**, **Loughran TP Jr**, Claxton DE, Fox TE, Kester M. FASEB J. 2022 Oct;36(10):e22514. doi: 10.1096/fj.202200765R. PMID: 36106439

Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia. Fisher-Wellman KH, Hagen JT, Kassai M, Kao LP, Nelson MAM, McLaughlin KL, Coalson HS, Fox TE, Tan SE, **Feith DJ**, Kester M, **Loughran TP Jr**, Claxton DE, Cabot MC. FASEB J. 2022 Jan;36(1):e22094. doi: 10.1096/fj.202101194RRR. PMID: 34888943

miR-181a is a novel player in the STAT3-mediated survival network of TCR $\alpha\beta$ + CD8+ T large granular lymphocyte leukemia. Assmann JLC, Leon LG, Stavast CJ, van den Bogaardt SE, Schilperoord-Vermeulen J, Sandberg Y, Bellido M, Erkeland SJ, **Feith DJ**, **Loughran TP Jr**, Langerak AW. Leukemia. 2022 Apr;36(4):983-993. doi: 10.1038/s41375-021-01480-2. Epub 2021 Dec 6. PMID: 34873301

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, **Dreicer R**, Srinivas S, Lorient Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. PMID: 35690072 Clinical Trial.

Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Morgans AK, Chen YH, Jarrard DE, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, **Dreicer R**, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, Cella D, Sweeney CJ; ECOG-ACRIN E3805 Investigators. Prostate. 2022 Sep;82(12):1176-1185. doi: 10.1002/pros.24369. Epub 2022 May 10. PMID: 35538398 Clinical Trial.

EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, **Devitt M**, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, **Dreicer R**, Gill PS. J Clin Oncol. 2023 Jan 20;41(3):640-650. doi: 10.1200/JCO.21.02923. Epub 2022 Aug 19. PMID: 35984996 Clinical Trial.

PUBLICATIONS

Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia. Douvas MG, Riegler LL. Curr Hematol Malig Rep. 2022 Feb;17(1):15-24. doi: 10.1007/s11899-021-00657-x. Epub 2021 Nov 4. PMID: 34735688 Review.

Diagnosis and Management of Atypical Chronic Myeloid Leukemia with a t(2;13)(q33;q12) Translocation. Wang JS, Elghawry O, Kurpiel BR, Douvas MG. Case Rep Hematol. 2022 May 4;2022:4628183. doi: 10.1155/2022/4628183. eCollection 2022. PMID: 35571528

Bispespecific antibodies for the treatment of breast cancer. Dillon PM, Tushir-Singh J, Lum LG. Expert Opin Biol Ther. 2022 Aug;22(8):1017-1027. doi: 10.1080/14712598.2021.1922665. Epub 2021 May 9. PMID: 33896311 Review.

Desmoid Tumor and Implant-Based Breast Reconstruction. Kilmartin C, Westover C, Raghavan S, Dillon PM, Campbell CA. Case Rep Oncol. 2023 Feb 14;16(1):74-80. doi: 10.1159/000525350. eCollection 2023 Jan-Dec. PMID: 36817360

Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy. Harris AR, Esparza S, Azimi MS, Cornelison R, Azar FN, Llaneza DC, Belanger M, Mathew A, Tkachenko S, Perez MJ, Rosean CB, Bostic RR, Cornelison RC, Tate KM, Peirce-Cottler SM, Paquette C, Mills A, Landen CN, Saucerman J, Dillon PM, Pompano RR, Rutkowski MA, Munson JM. Front Oncol. 2022 Mar 17;12:801764. doi: 10.3389/fonc.2022.801764. eCollection 2022. PMID: 35372032

Coffee and energy drink use patterns in college freshmen: associations with adverse health behaviors and risk factors. Svikis DS, Dillon PM, Meredith SE, Thacker LR, Polak K, Edwards AC, Pomm D, Dick D, Kendler K; Spit for Science Working Group. BMC Public Health. 2022 Mar 26;22(1):594. doi: 10.1186/s12889-022-13012-3. PMID: 35346128

Elaeostrol (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. PMID: 35584336 Clinical Trial.

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TE, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. BJU Int. 2022 Nov;130(5):592-603. doi: 10.1111/bju.15603. Epub 2021 Oct 25. PMID: 34597472

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TE, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Jang A, Barata P, Sonpavde G, Yu EY, Montgomery RB, Grivas P, Khaki AR. Clin Genitourin Cancer. 2022 Oct;20(5):e440-e452. doi: 10.1016/j.clgc.2022.06.001. Epub 2022 Jun 5. PMID: 35778337

Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TE, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Clin Genitourin Cancer. 2022 Apr;20(2):165-175. doi: 10.1016/j.clgc.2021.12.012. Epub 2021 Dec 17. PMID: 35078711

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TE, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Clin Genitourin Cancer. 2022 Dec;20(6):558-567. doi: 10.1016/j.clgc.2022.08.006. Epub 2022 Aug 19. PMID: 36155169

DIVISION OF HEMATOLOGY & ONCOLOGY

PUBLICATIONS

Adenosquamous carcinoma of the prostate with low PSMA expression. Isharwal S, Devitt M, Gupta S, Mithqal A, Tandon YK. Int Urol Nephrol. 2023 Mar;55(3):613-615. doi: 10.1007/s11255-022-03428-6. Epub 2022 Dec 20. PMID: 36538273 No abstract available.

Caspase 9b Drives Cellular Transformation, Lung Inflammation, and Lung Tumorigenesis. Kim M, Vu NT, Wang X, Bulut GB, Wang MH, Uram-Tuculescu C, Pillappa R, Kim S, Chalfant CE. Mol Cancer Res. 2022 Aug 5;20(8):1284-1294. doi: 10.1158/1541-7786.MCR-21-0905. PMID: 35412615

Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina. Mondal K, Porter H, Cole J 2nd, Pandya HK, Basu SK, Khanam S, Chiu CY, Shah V, Stephenson DJ, Chalfant CE, Mandal N. Mol Neurobiol. 2022 Jun;59(6):3873-3887. doi: 10.1007/s12035-022-02825-3. Epub 2022 Apr 15. PMID: 35426574

Correction: Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina. Mondal K, Porter H, Cole J 2nd, Pandya HK, Basu SK, Khanam S, Chiu CY, Shah V, Stephenson DJ, Chalfant CE, Mandal N. Mol Neurobiol. 2022 Oct;59(10):6611. doi: 10.1007/s12035-022-02975-4. PMID: 35904716 No abstract available.

Ceramide kinase regulates acute wound healing by suppressing 5-oxo-EETE biosynthesis and signaling via its receptor OXER1. Maus KD, Stephenson DJ, Ali AN, MacKnight HP, Huang HJ, Serrats J, Kim M, Diegelmann RF, Chalfant CE. J Lipid Res. 2022 Apr;63(4):100187. doi: 10.1016/j.jlr.2022.100187. Epub 2022 Feb 24. PMID: 35219746

Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition. Madanayake TW, Welsh EA, Darville LNF, Koomen JM, Chalfant CE, Haura EB, Robinson TJ. Nucleic Acid Ther. 2022 Oct;32(5):391-400. doi: 10.1089/nat.2021.0101. Epub 2022 Jul 20. PMID: 35861718

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Blood Adv. 2022 Jan 11;6(1):339-357. doi: 10.1182/bloodadvances.2021004916. PMID: 34547770

Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia. Varadarajan I, Ballen K. Front Oncol. 2022 Feb 11;12:781479. doi: 10.3389/fonc.2022.781479. eCollection 2022. PMID: 35223471 Review.

Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference? El Chaer F, Ballen KK. Bone Marrow Transplant. 2022 Oct;57(10):1473-1474. doi: 10.1038/s41409-022-01765-9. Epub 2022 Jul 28. PMID: 35902643 No abstract available.

Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults. Amrein P, Ballen K, Stevenson K, Brunner A, Hobbs G, Hock H, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, McGreggor K, Macrea M, Burke M, Behnam T, Som T, Ramos A, Vartanian M, Lombardi Story J, Connolly C, Blonquist T, Neuberg D, Fathi A. Leuk Lymphoma. 2022 Jun;63(6):1428-1435. doi: 10.1080/10428194.2021.2018582. Epub 2022 Jan 25. PMID: 35075985

Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Shah A, Storek J, Woolson R, Pinckney A, Keyes-Elstein L, Wallace PK, Sempowski GD, McSweeney P, Mayes MD, Crofford L, Csuka ME, Phillips K, Khanna D, Simms R, Ballen K, LeClerc S, Clair WS, Nixon AB, Nash R, Wener M, Brasington R, Silver R, Griffith LM, Furst DE, Goldmuntz E, Sullivan KM. Rheumatology (Oxford). 2022 Oct 6;61(10):4155-4162. doi: 10.1093/rheumatology/keac015. PMID: 35108379

Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation Reed DR, Petroni GR, West M, Jones C, Alfaraj A, Williams PG, DeGregory K, Grose K, Monson S, Varadarajan I, Volodin L, Donowitz GR, Kindwall-Keller TL, Ballen KK. Hematol Oncol Stem Cell Ther. 2023 Jan 12;16(1):61-69. doi: 10.1016/j.hemone.2021.05.001. PMID: 36634280

PUBLICATIONS

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, **Ballen K**, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. *Haematologica*. 2023 Feb 9. doi: 10.3324/haematol.2022.281958. Online ahead of print. PMID: 36779595

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SE, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, **Ayers EC**, Landsburg DJ, Echalié B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, **Portell CA**. *Blood*. 2022 Jan 20;139(3):413-423. doi: 10.1182/blood.2021012888. PMID: 34570876

Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner-Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, **Portell CA**, Landsburg DJ, **Ayers EC**, Castillo JJ. *Am J Hematol*. 2023 Feb;98(2):300-308. doi: 10.1002/ajh.26784. Epub 2023 Jan 1. PMID: 36588409

Zhang, Y. -W., Torsilieri, H. M., & Casanova, J. E. (2022). Quantitation of RhoA activation: differential binding to downstream effectors.. *Small GTPases*, 13(1), 296-306. doi:[10.1080/21541248.2022.2111945](https://doi.org/10.1080/21541248.2022.2111945)

miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4. Xie X, Shirasu T, Li J, Guo LW, Kent KC. *Cell Death Discov*. 2023 Feb 22;9(1):73. doi: 10.1038/s41420-023-01364-7. PMID: 36813774

Portell, C. A., Wages, N. A., Kahl, B. S., Budde, L. E., Chen, R. W., Cohen, J. B., Varhegyi N.E., Petroni G.R., **Williams, M. E.** (2022). Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.. *Blood Adv*, 6(5), 1490-1498. doi:[10.1182/bloodadvances.2021005357](https://doi.org/10.1182/bloodadvances.2021005357)

Rusconi, C., Cheah, C. Y., Eyre, T. A., Tucker, D., Klener, P., Giné, E., Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, **Williams ME**, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C (2022). Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.. *Blood*, 140(17), 1907-1916. doi:[10.1182/blood.2022015560](https://doi.org/10.1182/blood.2022015560)

Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction. Xie X, Guo LW, Kent CK. *Cell Death Discov*. 2022 Sep 12;8(1):382. doi: 10.1038/s41420-022-01178-z. PMID: 36096890 No abstract available.

Angioplasty induces epigenomic remodeling in injured arteries. Zhang M, Urabe G, Ozer HG, Xie X, Webb A, Shirasu T, Li J, Han R, Kent KC, Wang B, Guo LW. *Life Sci Alliance*. 2022 Feb 15;5(5):e202101114. doi: 10.26508/lsa.202101114. Print 2022 May. PMID: 35169042

Repositioning Fenofibrate to Reactivate p53 and Reprogram the Tumor-Immune Microenvironment in HPV+ Head and Neck Squamous Cell Carcinoma. O'Neill WQ, Xie X, Gui S, Yu H, Davenport J, Cartwright T, Storl-Desmond M, Ryu E, Chan ER, Cao S, Fu P, Teknos TN, Pan Q. *Cancers (Basel)*. 2022 Jan 7;14(2):282. doi: 10.3390/cancers14020282. PMID: 35053444

Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. *Eur Urol Focus*. 2023 Feb 28:S2405-4569(23)00048-2. doi: 10.1016/j.euf.2023.02.008. Online ahead of print. PMID: 36863962

Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. *Cancers (Basel)*. 2022 Jun 30;14(13):3233. doi: 10.3390/cancers14133233. PMID: 35805010

PUBLICATIONS

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, Koh LP, Jagasia MH, Valcarcel D, Maziarz RT, Keating AK, Hwang WYK, Rezvani AR, Karras NA, Fernandes JF, Rocha V, Badell I, Ram R, Schiller GJ, **Volodin L**, Walters MC, Hamerschlak N, Cilloni D, Frankfurt O, McGuirk JP, Kurtzberg J, Sanz G, Simantov R, Horwitz ME. *Transplant Cell Ther.* 2023 Feb 10;S2666-6367(23)01071-0. doi: 10.1016/j.jtct.2023.01.031. Online ahead of print. PMID: 36775201

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CP, Kwon M, Clausen J, **Volodin L**, Giebel S, Chacon MJ, Meyers G, Ghosh M, Deeren D, Sanz J, Morariu-Zamfir R, Arbushites M, Lakshminarayanan M, Barbour AM, Chen YB. *Lancet Haematol.* 2022 Jan;9(1):e14-e25. doi: 10.1016/S2352-3026(21)00367-7. PMID: 34971577 Clinical Trial.

Therapeutic potential of Pogostemon cablin herb: a comprehensive review. **Thakur A.** *Pharm Pat Anal.* 2022 Dec 13. doi: 10.4155/ppa-2022-0021. Online ahead of print. PMID: 36511100 Review.

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. Kubicka E, **Lum LG, Huang M, Thakur A.** *Front Immunol.* 2022 Nov 1;13:899468. doi: 10.3389/fimmu.2022.899468. eCollection 2022. PMID: 36389764

Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. Vaishampayan UN, **Thakur A**, Chen W, Deol A, Patel M, Dobson K, Dickow B, Schalk D, Schienschang A, Whitaker S, Polend A, Fontana JA, Heath EI, **Lum LG.** *Clin Cancer Res.* 2023 Jan 4;29(1):122-133. doi: 10.1158/1078-0432.CCR-22-1601. PMID: 36255393 Clinical Trial.

Review of ¹³carbon nuclear magnetic resonance characterizations of dimethyltin carboxylates. Kaur H, **Thakur A.** *Heliyon.* 2022 Sep 8;8(9):e10507. doi: 10.1016/j.heliyon.2022.e10507. eCollection 2022 Sep. PMID: 36148282 Review.

Monkeypox Disease Outbreak (2022): Correspondence: Authors' Reply. Lahariya C, **Thakur A**, Dudeja N. *Indian Pediatr.* 2022 Sep 15;59(9):730-731. PMID: 36101960 No abstract available.

Monkeypox Disease Outbreak (2022): Epidemiology, Challenges, and the Way Forward. Lahariya C, **Thakur A**, Dudeja N. *Indian Pediatr.* 2022 Aug 15;59(8):636-642. doi: 10.1007/s13312-022-2578-2. Epub 2022 Jun 27. PMID: 35762024 Review.

An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy. Chan S, Belmar N, Ho S, Rogers B, Stickler M, Graham M, Lee E, Tran N, Zhang D, Gupta P, Sho M, MacDonough T, Woolley A, Kim H, Zhang H, Liu W, Zheng P, Dezso Z, Halliwill K, Ceccarelli M, Rhodes S, **Thakur A**, Forsyth CM, Xiong M, Tan SS, Iyer R, Lake M, Digiammarino E, Zhou L, Bigelow L, Longenecker K, Judge RA, Liu C, Trumble M, Remis JP, Fox M, Cairns B, Akamatsu Y, Hollenbaugh D, Harding F, Alvarez HM. *Nat Cancer.* 2022 Mar;3(3):337-354. doi: 10.1038/s43018-022-00334-9. Epub 2022 Mar 7. PMID: 35256819

Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile. Sturek JM, Thomas TA, Gorham JD, Sheppard CA, Raymond AH, Petros De Guex K, Harrington WB, Barros AJ, Madden GR, Alkabab YM, Lu DY, Liu Q, Poulter MD, Mathers AJ, **Thakur A**, Schalk DL, Kubicka EM, **Lum LG**, Heysell SK. *Microbiol Spectr.* 2022 Feb 23;10(1):e0256021. doi: 10.1128/spectrum.02560-21. Epub 2022 Feb 23. PMID: 35196802 Clinical Trial.

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. Qiao G, Kone LB, Phillips EH, Lee SS, Brown GE, Khetani SR, **Thakur A, Lum LG**, Prabhakar BS, Maker AV. *Oncogene.* 2022 Apr;41(14):2054-2068. doi: 10.1038/s41388-022-02209-w. Epub 2022 Feb 17. PMID: 35177811

Novel PE and APC tandems: Additional near-infrared fluorochromes for use in spectral flow cytometry. Seong Y, Nguyen DX, Wu Y, **Thakur A**, Harding F, Nguyen TA. *Cytometry A.* 2022 Oct;101(10):835-845. doi: 10.1002/cyto.a.24537. Epub 2022 Feb 2. PMID: 35112484

Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer. Altshuler E, Franke AJ, **Skelton WP 4th**, Feely M, Wang Y, Lee JH, Read T, Terracina K, Lou XY, Dai Y, George TJ. *Clin Colorectal Cancer.* 2022 Sep 30;S1533-0028(22)00104-9. doi: 10.1016/j.clcc.2022.09.004. Online ahead of print. PMID: 36319582

Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Zhang Y, Kumar P, Adashek JJ, **Skelton WP 4th**, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. *Cells.* 2022 Aug 12;11(16):2505. doi: 10.3390/cells11162505. PMID: 36010582

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. Adib E, El Zarif T, Jain RK, **Skelton WP 4th**, Freeman D, Curran C, Akl E, Nassar AH, Ravi P, Mantia C, Kwiatkowski DJ, Choueiri TK, Sonpavde G. *BJUI Compass.* 2022 Mar;3(2):169-172. doi: 10.1002/bco2.125. Epub 2021 Nov 10. PMID: 35224552

PUBLICATIONS

Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations. Hoskins EL, Samorodnitsky E, Wing MR, Reeser JW, Hopkins JF, Murugesan K, Kuang Z, Vella R, Stein L, Risch Z, Yu L, Adebola S, Paruchuri A, Carpten J, Chahoud J, Edge S, Kolesar J, McCarter M, Nepple KG, **Reilley M**, Scaife C, Tripathi A, Single N, Huang RSP, Albacker LA, Roychowdhury S. JCO Precis Oncol. 2023 Jan;7:e2200300. doi: 10.1200/PO.22.00300. PMID: 36623238

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer. Sorah JD, Moore DT, **Reilley MJ**, Salem ME, Triglianios T, Sanoff HK, McRee AJ, Lee MS. Oncologist. 2022 Dec 9;27(12):1006-e930. doi: 10.1093/oncolo/oyac222. PMID: 36288238 Clinical Trial.

Real-World Experience of Combined Treatment with Azacitidine and Romidepsin in Patients with Peripheral T-Cell Lymphoma. Kalac M, Jain S, Tam CS, Xiao Z, Montanari F, Kanakry JA, Huber BD, Goldfinger M, **O'Connor OA**, **Marchi E**. Blood Adv. 2023 Feb 15;bloodadvances.2022009445. doi: 10.1182/bloodadvances.2022009445. Online ahead of print. PMID: 36790924 No abstract available.

Clonal cutaneous and neurosyphilis: A pitfall in pseudolymphoma diagnosis. Yi LG, Rusu CA, Cropley TG, **Marchi E**, Gru AA, Greer KE, Raghavan SS. J Cutan Pathol. 2022 Mar;49(3):288-292. doi: 10.1111/cup.14153. Epub 2021 Nov 5. PMID: 34655438

A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma. Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, Hess BT, Isaac KM, **Portell CA**, Mejia Garcia AV, Goldsmith SR, Grover NS, Riedell PA, Karmali R, Burkart M, Buege M, Akhtar OS, Torka P, Kumar A, Hill BT, Kahl BS, Cohen JB. Blood Adv. 2023 Feb 21;bloodadvances.2022008916. doi: 10.1182/bloodadvances.2022008916. Online ahead of print. PMID: 36809796

A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. Cortese MJ, Wei W, Cerdeña S, Watkins MP, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Namoglu E, Grover NS, Snow A, Orellana-Noia V, Rainey M, Sohail M, Rudoni J, **Portell C**, Voorhees T, Landsburg DJ, Kamdar M, Kahl BS, Hill BT. Leuk Lymphoma. 2023 Jan;64(1):107-118. doi: 10.1080/10428194.2022.2140281. Epub 2022 Nov 2. PMID: 36323309

CNS prophylaxis in DLBCL: first do no harm. **Portell CA**. Blood. 2022 Apr 21;139(16):2420-2421. doi: 10.1182/blood.2022015432. PMID: 35446381 No abstract available.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Surenda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. PMID: 34891224 Clinical Trial.

Uterine Artery Embolisation of Fibroids and the Phenomenon of Post-Embolisation Syndrome: A Systematic Review. Waldron MG, Kassamani YW, O'Mahony AT, O'Mahony SM, O'Sullivan OE, Power SP, Spence L, Maher MM, **O'Connor OJ**, Buckley MM. Diagnostics (Basel). 2022 Nov 23;12(12):2916. doi: 10.3390/diagnostics12122916. PMID: 36552922 Review.

An evaluation of the impact of the Coronavirus (COVID 19) pandemic on interventional radiographers' wellbeing. Murphy M, Moore N, Leamy B, England A, **O'Connor OJ**, McEntee ME. J Med Imaging Radiat Sci. 2022 Sep;53(3):384-395. doi: 10.1016/j.jmir.2022.05.006. Epub 2022 May 18. PMID: 35660274

Inhibition of casein kinase 1δ disrupts translation initiation and exerts potent antilymphoma activity. Pal I, Grilo AMS, Gaspary A, Das Sharma S, Scotto L, **O'Connor OA**, Jovanovic M, Deng C, Berchowitz LE. Blood Adv. 2022 Jul 26;6(14):4157-4161. doi: 10.1182/bloodadvances.2021006833. PMID: 35613464 No abstract available.

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trümper L, Ilidge T, **O'Connor OA**, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. PMID: 35470385 Clinical Trial.

An evaluation of information online on artificial intelligence in medical imaging. Mulryan P, Ni Chleirigh N, O'Mahony AT, Crowley C, Ryan D, McLaughlin P, McEntee M, Maher M, **O'Connor OJ**. Insights Imaging. 2022 Apr 25;13(1):79. doi: 10.1186/s13244-022-01209-4. PMID: 35467250

DeLTA 2.0: A deep learning pipeline for quantifying single-cell spatial and temporal dynamics. **O'Connor OM**, Alnahhas RN, Lugagne JB, Dunlop MJ. PLoS Comput Biol. 2022 Jan 18;18(1):e1009797. doi: 10.1371/journal.pcbi.1009797. eCollection 2022 Jan. PMID: 35041653

PUBLICATIONS

Making computed tomography safer for patients with Crohn's disease. O'Grady J, Carey BW, Kavanagh RG, O'Connell A, **O'Connor OJ**, Kenny-Walsh E, Zulquernain SA, Maher MM, Shanahan F, Scand J Gastroenterol. 2022 Feb;57(2):175-182. doi: 10.1080/00365521.2021.1994640. Epub 2021 Oct 26. PMID: 34699288 Clinical Trial.

Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer. Ward KA, Muller DA, Dutta SW, Malhi J, Sanders JC, Luminais CK, **Millard TA**, Showalter TN, Showalter SL, Janowski EM. Clin Breast Cancer. 2023 Feb 1:S1526-8209(23)00027-7. doi: 10.1016/j.clbc.2023.01.012. Online ahead of print. PMID: 36868913

A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim. Mort J, Maheshwari S, Basu N, **Dillon P**, Brady K, Bear H, **Millard T**. Case Rep Oncol Med. 2022 Feb 23;2022:7295305. doi: 10.1155/2022/7295305. eCollection 2022. PMID: 35251725

Including partners in discussions of sexual side effects from breast cancer: a qualitative study of survivors, partners, and providers. Shaffer KM, Kennedy E, Glazer JV, Clayton AH, Cohn W, Reese JB, **Millard TA**, Ingersoll KS, Ritterband LM, Showalter S. Support Care Cancer. 2022 Jun;30(6):4935-4944. doi: 10.1007/s00520-022-06917-7. Epub 2022 Feb 17. PMID: 35178587

Broad reactivity and enhanced potency of recombinant anti-EGFR \times anti-CD3 bispecific antibody-armed activated T cells against solid tumours. Huang MTF, Sharma V, Mendelsohn A, Wei Q, Li J, Yu B, Larrick JW, **Lum LG**. Ann Med. 2022 Dec;54(1):1047-1057. doi: 10.1080/07853890.2022.2059101. PMID: 36799362

Disparate Regions of the Human Chemokine CXCL10 Exhibit Broad-Spectrum Antimicrobial Activity against Biodefense and Antibiotic-Resistant Bacterial Pathogens. Crawford MA, Ward AE, Gray V, Bailer P, Fisher DJ, Kubicka E, Cui Z, Luo Q, Gray MC, Criss AK, **Lum LG**, Tamm LK, Letteri RA, Hughes MA. ACS Infect Dis. 2023 Jan 13;9(1):122-139. doi: 10.1021/acsinfecdis.2c00456. Epub 2022 Dec 7. PMID: 36475632

A Review of the Past, Present and Future of Cancer-associated Thrombosis Management. Ramcharitar RK, **Man L**, Khaja MS, Barnett ME, Sharma A. Heart Int. 2022 Aug 23;16(2):117-123. doi: 10.17925/HI.2022.16.2.117. eCollection 2022. PMID: 36721704 Review.

A Brief Review of Thrombolytics for Venous Interventions. Grewal SK, Hedrick AL, **Man L**, Sharma AM, Desai KR, Khaja MS. Semin Intervent Radiol. 2022 Nov 17;39(4):394-399. doi: 10.1055/s-0042-1757318. eCollection 2022 Aug. PMID: 36406029 Review.

Cardiac complications from multisystem inflammatory syndrome associated with prior COVID-19 infection. Patel K, Mehta R, Betz YM, **Man LM**. BMJ Case Rep. 2022 Aug 23;15(8):e249889. doi: 10.1136/bcr-2022-249889. PMID: 35999019

Images in Vascular Medicine Pectoralis minor syndrome - A forgotten vascular compression syndrome. Ramcharitar RK, Elghawy O, **Man L**, Sharma AM, Peruri A, Park AW, Norton P, Khaja M, Tripathi R. Vasc Med. 2022 Oct;27(5):518-520. doi: 10.1177/1358863X221110925. Epub 2022 Jul 25. PMID: 35879910 No abstract available.

Cancer Prevention from the Viewpoint of UVA Comprehensive Cancer Center. **Loughran TP**, Cohn W, Bonilla G, Anderson RT. Cancer Prev Res (Phila). 2022 Oct 10:OF1-OF6. doi: 10.1158/1940-6207.CAPR-22-0365. Online ahead of print. PMID: 36318178

Cancer Prevention from the Viewpoint of UVA Comprehensive Cancer Center. **Loughran TP**, Cohn W, Bonilla G, Anderson RT. Cancer Prev Res (Phila). 2022 Nov 1;15(11):715-720. doi: 10.1158/1940-6207.CAPR-22-0365. PMID: 36317368

Ty δ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. Barilà G, Grassi A, Cheon H, Teramo A, Calabretto G, Chahal J, Vicenzetto C, Almeida J, Shemo BC, Shi M, Gasparini VR, Munoz-Garcia N, Pastoret C, Nakazawa H, Oshimi K, Sokol L, Ishida F, Lamy T, Orfao A, Morice WG, **Loughran TP**, Semenzato G, Zambello R. Blood. 2023 Mar 2;141(9):1036-1046. doi: 10.1182/blood.2021013489. PMID: 36096473

Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. LeBlanc FR, Hasanali ZS, Stuart A, Shimko S, Sharma K, Leshchenko VV, Parekh S, Fu H, Zhang Y, Martin MM, Kester M, Fox T, Liao J, **Loughran TP**, Evans J, Pu JJ, Spurgeon SE, Aladjem MI, Epner EM. Oncotarget. 2022 Aug 16;13:986-1002. doi: 10.18632/oncotarget.28258. eCollection 2022. PMID: 36093297_

Allogeneic Bone Marrow Transplant as a Cure for Refractory T-Cell Large Granular Lymphocytic Leukemia in an Adolescent. Fries C, Evans AG, Cheon H, Korones DN, **Loughran TP Jr**, Andolina JR. J Pediatr Hematol Oncol. 2022 Aug 1;44(6):e960-e963. doi: 10.1097/MPH.0000000000002390. Epub 2021 Dec 29. PMID: 35895317

PUBLICATIONS

Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Huuhtanen J, Bhattacharya D, Lönnberg T, Kankainen M, Kerr C, Theodoropoulos J, Rajala H, Gurnari C, Kasanen T, Braun T, Teramo A, Zambello R, Herling M, Ishida F, Kawakami T, Salmi M, **Loughran T**, Maciejewski JP, Lähdesmäki H, Kelkka T, Mustjoki S. Nat Commun. 2022 Apr 11;13(1):1981. doi: 10.1038/s41467-022-29173-z. PMID: 35411050

Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. Mundy-Bosse BL, Weigel C, Wu YZ, Abdelbaky S, Youssef Y, Casas SB, Polley N, Ernst G, Young KA, McConnell KK, Nalin AP, Wu KG, Broughton M, Lordo MR, Altynova E, Hegewisch-Sollosa E, Enriquez-Vera DY, Dueñas D, Barrionuevo C, Yu SC, Saleem A, Suarez CJ, Briercheck EL, Molina-Kirsch H, **Loughran TP**, Weichenhan D, Plass C, Reneau JC, Mace EM, Gamboa FV, Weinstock DM, Natkunam Y, Caligiuri MA, Mishra A, Porcu P, Baiocchi RA, Brammer JE, Freud AG, Oakes CC. Blood Cancer Discov. 2022 Mar 1;3(2):154-169. doi: 10.1158/2643-3230.BCD-21-0098. PMID: 35247900

Electronic health record risk-stratification tool reduces venous thromboembolism events in surgical patients. Rastogi R, Lattimore CM, Mehaffey JH, Turrentine FE, **Maitland HS**, Zaydfudim VM. Surg Open Sci. 2022 Apr 26;9:34-40. doi: 10.1016/j.sopen.2022.04.003. eCollection 2022 Jul. PMID: 35620709

Fabrication of Porous Fe-Based Metal-Organic Complex for the Enhanced Delivery of 5-Fluorouracil in In Vitro Treatment of Cancer Cells. Le BT, Nguyen CQ, Nguyen PT, Ninh HD, **Le TM**, Nguyen PTH, La DD. ACS Omega. 2022 Dec 9;7(50):46674-46681. doi: 10.1021/acsomega.2c05614. eCollection 2022 Dec 20. PMID: 36570299

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. Johnson M, Dudek AZ, Sukari A, Call J, **Kunk PR**, Lewis K, Gainor JF, Sarantopoulos J, Lee P, Golden A, Harney A, Rothenberg SM, Zhang Y, Goldman JW. Clin Cancer Res. 2022 Jun 13;28(12):2517-2526. doi: 10.1158/1078-0432.CCR-21-3009. PMID: 35302585 Clinical Trial.

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, **El Chaer F**, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363. PMID: 36881031

How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines. **El Chaer F**, Hourigan CS, Zeidan AM. Blood. 2023 Feb 9;blood.2022017808. doi: 10.1182/blood.2022017808. Online ahead of print. PMID: 36758209

How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. **El Chaer F**, Auletta JJ, Chemaly RE. Blood. 2022 Aug 18;140(7):673-684. doi: 10.1182/blood.2022016089. PMID: 35776899

UVA Cancer Center Receives Prestigious Award for Patient Care (CBS19)



The University of Virginia Cancer Center West Hematology and Oncology Clinic received a prestigious award for the third consecutive year for its staff's care over the past year.

WATCH

DIVISION OF HEMATOLOGY & ONCOLOGY

STAFF PROFILE - Stephanie Shifflett



Tell us a little bit about yourself.

I've been at the University of Virginia for seven and a half years after spending a brief term as Assistant Controller with Aramark. Before that, I spent 14 years working at James Madison University as a Senior Fiscal Technician. I live in Elkton, Virginia, with my oldest granddaughter London, and dog, Mya.

What brought you to Charlottesville?

After spending many years at JMU, there wasn't much opportunity for growth.

What excites you about your work?

I enjoy a challenge. Working in a financial field offers much of that, especially when you start mixing various funding sources....only a few will get that.

Proudest/greatest achievement outside the professional realm?

My family. I spent 28 wonderful years with my husband until he passed away almost two years ago from AML. We have two daughters and four precious grandchildren.

Next life?

Hopefully, enjoying my retirement traveling wherever my heart desires.

What are you usually doing in spare time?

My newly found favorite exercise!

Favorite vacation/activity spot?

Gulf coast beaches and the Shenandoah National Park.

Most admired person, and why?

My oldest daughter, Brittany. She has been my rock and biggest supporter throughout the loss of her father. She is an amazing mother and the most hard-working young adult I've ever met.



Best advice anyone ever gave you?

Be kind to yourself, and never let society dictate when you should achieve certain goals



DIVISION OF HEMATOLOGY & ONCOLOGY

APP PROFILE - Marie Thomas



Tell us a little bit about yourself.

I've been at UVA for five years as a Nurse Practitioner in Hematology/Oncology. Before that, I worked and lived in Charleston, SC, for about seven years. I worked as an inpatient Surgical Oncology nurse for almost five years at the Medical University of South Carolina (MUSC), where I did my schooling for both my BSN and DNP nursing degrees. I currently live in the town of Charlottesville in a 1900s farmhouse not far from the University of Virginia with my significant other and our wonderful fat cat.

What brought you to Charlottesville?

I moved here for my first position as a Nurse Practitioner shortly after graduating from the DNP program.

What excites you about your work?

The strong connections I build with my patients and their loved ones is what I love most about my job. I am also fortunate to work with wonderful colleagues

and feel we work very well as a team.

Proudest/greatest achievement outside the professional realm?

Completing four full marathons.

Next life?

In my next life, I dream of being a comedian and cast member on Saturday Night Live.

What are you usually doing in spare time?

I enjoy running, traveling, listening to Taylor Swift, sharing laughs, and making memories with my family and friends. Sometimes I enjoy being lazy and binging something on Netflix while cuddling with my cat.

Favorite vacation/activity spot?

The beaches of North and South Carolina as well as Jackson Hole, WY

Most admired person, and why?

I would have to say both my mother and father. They both taught me incredible work ethic and how to be caring, loving, and supportive of others no matter what. My mother is a resilient and fantastic woman who has guided our family as a strong matriarch. My father had a wonderfully optimistic outlook and created many relationships with his infectious attitude.

Best advice anyone ever gave you?

"May the Wig be with You." It is an inside family motto with a pun on Star Wars, but one that is very meaningful within our family.




What about you would surprise us?

I love to have dance parties anywhere at any time.



DIVISION OF HEMATOLOGY & ONCOLOGY

RESEARCH FACULTY PROFILE - Erik Hendrickson



Tell us a little bit about yourself.

I've been at the University of Virginia for 0.3 years, after a brief career as a grocery bagger (Meijer Thrifty Acres) and a postal clerk. My main early accomplishment was that the expression "going postal" did not reference any behavior I exhibited during my USPS career. I have been involved in academic laboratory research for 48 years, which, if you are good at doing math, will alert you that I'm getting to the end of my professional road. I live on a small farm in Charlottesville (Free Union area) with my wife, four cats, two horses, and our collection of antique typewriters: I'll see you and raise you a Blickensderfer.

What brought you to Charlottesville?

I came to Cville solely at the urging of my wife, Dr. Anja-Katrin Bielinsky, the new chairperson of the Biochemistry and Genetics department. Happy

wife, happy life.

What excites you about your work?

Discovery. Finding out stuff that nobody in the world knows about turns out to be fun.

Proudest/greatest achievement outside the professional realm?

I am a two-time national bridge champion.

Next life?

Don't believe in the afterlife – it's a cold, black void. Regarding retirement, I hope to garden, walk long-distance (think AT and PCT trails), and play as much bridge as possible.

What are you usually doing in spare time?

Playing bridge, gardening and/or motorcycling.

Favorite vacation/activity spot?

Acadia National Park

Most admired person, and why?

Hank Williams. In 29 years, as a non-functioning alcoholic, Hank managed to pen 20-30 songs that will be forever in the music canon. Wolfgang Amadeus Mozart would be a close 2nd.

Best advice anyone ever gave you?

Do not waste your life filling out silly questionnaires.

What about you would surprise us?

My mile PR is 4:52.6



DIVISION OF HEMATOLOGY & ONCOLOGY

CLINICAL FACULTY PROFILE - Paul Skelton



Tell us a little bit about yourself.

My name is Paul Skelton, and I've been at the University of Virginia for eight months since August 2022 (time is flying by!). I was born and raised in Tampa, FL, and have three younger siblings. I went to Duke for undergrad, the University of Florida for medical school, residency, and a chief resident year, and Moffitt for fellowship before joining the UVA faculty here in Charlottesville.

What brought you to Charlottesville?

I focused on academic genitourinary medical oncology a few months after starting my Hematology/Oncology fellowship. When I was looking at potential jobs and interviewing for the last year of fellowship, I loved everything about UVA—the people, the hospital system, the job description and support, and especially the city of Charlottesville—all the historical sites. In the backdrop of beautiful mountains, it was exactly what I was looking for.

What excites you about your work?

Being able to care for a cancer patient is very humbling, and I want to make sure they get the best care possible. That motivates me to learn as much as I can about my field and my patients, and being able to conduct research and clinical trials to help advance and move the field forward is such a source of excitement for me.

Proudest/greatest achievement outside the professional realm?

Eagle Scout. The Boy Scouts of America was such a large part of my life growing up and helped teach me so much, from leadership skills and wilderness survival techniques like how to use a compass or start a fire to learning about things like Oceanography or Fish and Wildlife management. I remember the night I was awarded Eagle Scout and still reflect on the values and life lessons that scouting has taught me to this day.

What are you usually doing in spare time?

I love traveling, especially to National Parks and other units of the National Park Service, so having Shenandoah NP in our backyard is amazing—such great hiking and scenery there. I also love watching sports with friends, particularly Duke basketball and the Tampa Bay pro teams (Bucs/Lightning/Rays), but I have gotten into UVa sports since I've been in Cville (Go 'Hoos!). I also like exploring the city of Charlottesville and surrounding areas in my spare time, trying new restaurants and hiking trails.



Favorite vacation/activity spot?

Hard to name just one place, but if I had to pick, I'd say Singapore. A close second would be the American West—places like the Grand Canyon, Mesa, Delicate Arches, and the Great Sand Dunes are such amazing sights to see.

Most admired person, and why?

My mom and dad they've always been so loving and supportive of me through the years.

Best advice anyone ever gave you?

Always smile.

